Stomach Ulcers |
|
|
Clinical Trial: Omeprazole and Amoxicillin and/or Vitamin and Mineral Supplements and/or Garlic Supplements in Preventing Stomach Cancer in Patients With Precancerous Stomach Lesions
This study is not yet open for patient recruitment.
Verified by National Cancer Institute (NCI) August 2005
Purpose
RATIONALE: Chemoprevention is the use of certain drugs or supplements to keep cancer from forming, growing, or coming back. The use of omeprazole and amoxicillin and/or vitamin and mineral supplements and/or garlic supplements may prevent stomach cancer.
PURPOSE: This randomized clinical trial is studying omeprazole and amoxicillin and/or vitamin and mineral supplements and/or garlic supplements to see how well they work in preventing stomach cancer in patients with precancerous stomach lesions.
| Condition | Intervention |
|---|---|
| Gastric Cancer Precancerous Condition | Drug: amoxicillin Drug: ascorbic acid Drug: beta carotene Drug: garlic Drug: omeprazole Drug: selenium Drug: vitamin E Procedure: antibiotic therapy Procedure: biologically based therapies Procedure: cancer prevention intervention Procedure: chemoprevention of cancer Procedure: complementary and alternative therapy Procedure: dietary intervention Procedure: infection prophylaxis/management Procedure: nutritional supplementation Procedure: proton pump inhibitor therapy Procedure: supportive care/therapy |
MedlinePlus related topics: Cancer; Cancer Alternative Therapies; Stomach Cancer
Study Type: Interventional
Study Design: Prevention
Official Title: Randomized Study of Omeprazole and Amoxicillin and/or Vitamin and Mineral Supplementation Comprising Beta Carotene, Vitamin E, Ascorbic Acid, and Selenium and/or Garlic Supplementation for the Prevention of Gastric Cancer in Patients With Precancerous Gastric Lesions
OBJECTIVES:
Primary
- Compare the effectiveness of omeprazole and amoxicillin and/or vitamin and mineral supplementation comprising beta carotene, vitamin E, ascorbic acid, and selenium and/or garlic supplementation, in terms of lowering the prevalence of severe chronic atrophic gastritis, intestinal metaplasia, dysplasia, and gastric cancer in patients with precancerous gastric lesions.
Secondary
- Compare the effects of these regimens on the rates of transition among the precancerous histopathologic states in these patients.
- Compare the rate of Helicobacter pylori (H. pylori) eradication and reinfection in patients treated with these regimens.
- Compare the effect of these regimens on blood pressure in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to Helicobacter pylori (H. pylori) antibody status (positive vs negative) and gender. Patients with an initial H. pylori infection are randomized to 1 of 8 treatment arms (I-VIII). Patients testing negative for H. pylori are randomized to 1 of 4 treatment arms (IX-XII).
- Arm I: Patients receive oral omeprazole placebo and oral amoxicillin placebo twice daily for 2 weeks. Three months later, patients are re-evaluated for H. pylori infection. Patients with persistent H. pylori infection receive omeprazole placebo and amoxicillin placebo for an additional 2 weeks. Patients also receive oral vitamin and mineral supplement placebos comprising beta carotene placebo, vitamin E placebo, ascorbic acid placebo, and selenium placebo twice daily and oral garlic supplement placebo twice daily beginning after completion of the initial 2-week treatment period with omeprazole and amoxicillin placebos and continuing for 39 months.
- Arm II: Patients receive omeprazole and amoxicillin placebos and vitamin and mineral supplement placebos as in arm I. Patients also receive an oral garlic supplement twice daily beginning after completion of the initial 2-week treatment period with omeprazole and amoxicillin placebos and continuing for 39 months.
- Arm III:Patients receive omeprazole and amoxicillin placebos as in arm I. Patients also receive oral vitamin and mineral supplements comprising beta carotene, vitamin E, ascorbic acid, and selenium twice daily beginning after completion of the initial 2-week treatment period with omeprazole and amoxicillin placebos and continuing for 39 months and garlic supplement placebo as in arm I.
- Arm IV: Patients receive omeprazole and amoxicillin placebos as in arm I. Patients also receive vitamin and mineral supplements as in arm III and garlic supplement as in arm II.
- Arm V: Patients receive oral omeprazole and oral amoxicillin twice daily for 2 weeks. Three months later, patients are re-evaluated for H. pylori infection. Patients with persistent H. pylori infection receive omeprazole and amoxicillin for an additional 2 weeks. Patients also receive vitamin and mineral supplement placebos and garlic supplement placebo as in arm I.
- Arm VI: Patients receive omeprazole and amoxicillin as in arm V. Patients also receive vitamin and mineral supplement placebos as in arm I and garlic supplement as in arm II.
- Arm VII: Patients receive omeprazole and amoxicillin as in arm V. Patients also receive vitamin and mineral supplements as in arm III and garlic supplement placebo as in arm I.
- Arm VIII: Patients receive omeprazole and amoxicillin as in arm V. Patients also receive vitamin and mineral supplements as in arm III and garlic supplement as in arm II.
- Arm IX: Patients receive omeprazole and amoxicillin placebos, vitamin and mineral supplement placebos, and garlic supplement placebo as in arm I.
- Arm X: Patients receive omeprazole and amoxicillin placebos and vitamin and mineral supplement placebos as in arm I. Patients also receive garlic supplement as in arm II.
- Arm XI: Patients receive omeprazole and amoxicillin placebos as in arm I. Patients also receive vitamin and mineral supplements as in arm III and garlic supplement placebo as in arm I.
- Arm XII: Patients receive omeprazole and amoxicillin placebos as in arm I. Patients also receive vitamin and mineral supplements as in arm III and garlic supplement as in arm II.
After completion of study treatment, patients are followed at 3 months.
PROJECTED ACCRUAL: Approximately 3,600 patients (approximately 2,400 randomized to arms I-VIII [patients with Helicobacter pylori (H. pylori) infection] and 1,000 randomized to arms IX-XII [patients without H. pylori infection]) will be accrued for this study.
Eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed precancerous gastric lesions by gastroscopic examination
- Gastroscopic results must have been obtained through prior participation in an endoscopic survey conducted in Lindqu, Shandong Province, China
- At high risk for gastric cancer
- Resident of Lindqu, Shandong Province, China
PATIENT CHARACTERISTICS:
Age
- 35 to 69
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- No history of bleeding disorder
Hepatic
- No liver disease
Renal
- No renal disease
Cardiovascular
- No heart failure
Pulmonary
- No emphysema
Other
- Not pregnant
- No allergy to penicillin or similar drugs
- No cancer except resected nonmelanoma skin cancer
- No other life-threatening illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No prior treatment for Helicobacter pylori (H. pylori) infection
- No concurrent regular use of vitamin or mineral supplements
Location and Contact Information
Mitchel H. Gail, MD, PhD, Study Chair, National Cancer Institute (NCI)
More Information
Clinical trial summary from the National Cancer Institute''''s PDQ® database
Last Updated: August 23, 2005
Record first received: August 22, 2005
ClinicalTrials.gov Identifier: NCT00134121
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-30
Resources
- H. pylori and Peptic Ulcer (National Institute of Diabetes and Digestive and Kidney Diseases)
- Stomach Ulcers (HealthWorld)

Not Signed In -

